AVATROMBOPAG MALEATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for avatrombopag maleate and what is the scope of patent protection?
Avatrombopag maleate
is the generic ingredient in one branded drug marketed by Akarx Inc and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.Avatrombopag maleate has twenty-one patent family members in fourteen countries.
One supplier is listed for this compound.
Summary for AVATROMBOPAG MALEATE
| International Patents: | 21 |
| US Patents: | 1 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 16 |
| Clinical Trials: | 4 |
| Patent Applications: | 8 |
| What excipients (inactive ingredients) are in AVATROMBOPAG MALEATE? | AVATROMBOPAG MALEATE excipients list |
| DailyMed Link: | AVATROMBOPAG MALEATE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for AVATROMBOPAG MALEATE
Generic Entry Date for AVATROMBOPAG MALEATE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for AVATROMBOPAG MALEATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Chinese PLA General Hospital | Phase 4 |
| Eisai Inc. | Phase 3 |
| Eisai Inc. | Phase 2 |
US Patents and Regulatory Information for AVATROMBOPAG MALEATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akarx Inc | DOPTELET | avatrombopag maleate | TABLET;ORAL | 210238-001 | May 21, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Akarx Inc | DOPTELET | avatrombopag maleate | TABLET;ORAL | 210238-001 | May 21, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AVATROMBOPAG MALEATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Akarx Inc | DOPTELET | avatrombopag maleate | TABLET;ORAL | 210238-001 | May 21, 2018 | ⤷ Try a Trial | ⤷ Try a Trial |
| Akarx Inc | DOPTELET | avatrombopag maleate | TABLET;ORAL | 210238-001 | May 21, 2018 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for AVATROMBOPAG MALEATE
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Korea | 20040078122 | ⤷ Try a Trial | |
| European Patent Office | 2314586 | Dérivé 2-acylaminothiazole ou sel de celui-ci (2-Acylaminothiazole derivative or salt thereof) | ⤷ Try a Trial |
| Hungary | S1900052 | ⤷ Try a Trial | |
| Spain | 2610611 | ⤷ Try a Trial | |
| World Intellectual Property Organization (WIPO) | 03062233 | ⤷ Try a Trial | |
| Slovenia | 1466912 | ⤷ Try a Trial | |
| Luxembourg | C00137 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for AVATROMBOPAG MALEATE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1466912 | C201930073 | Spain | ⤷ Try a Trial | PRODUCT NAME: AVATROMBOPAG O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR MALEATO DE AVATROMBOPAG; NATIONAL AUTHORISATION NUMBER: EU/1/19/1373; DATE OF AUTHORISATION: 20190620; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1373; DATE OF FIRST AUTHORISATION IN EEA: 20190620 |
| 1466912 | 638 | Finland | ⤷ Try a Trial | |
| 1466912 | 2019/058 | Ireland | ⤷ Try a Trial | PRODUCT NAME: AVATROMBOPAG OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR AVATROMBOPAG MALEATE; REGISTRATION NO/DATE: EU/1/19/1373 20190624 |
| 1466912 | C20190040 00310 | Estonia | ⤷ Try a Trial | PRODUCT NAME: AVATROMBOPAAG;REG NO/DATE: EU/1/19/1373 24.06.2019 |
| 1466912 | 341 50024-2019 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: AVATROMBOPAG VO VSETKYCH FORMACH CHRANENYCH ZA- KLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/19/1373 20190624 |
| 1466912 | CR 2019 00057 | Denmark | ⤷ Try a Trial | PRODUCT NAME: AVATROMBOPAG ELLER FARMACEUTISK ACCEPTABLE SALTE DERAF, I SAERDELESHED AVATROMBOPAG MALEAT; REG. NO/DATE: EU/1/19/1373 20190624 |
| 1466912 | CA 2019 00057 | Denmark | ⤷ Try a Trial | PRODUCT NAME: AVATROMBOPAG MALEAT; REG. NO/DATE: EU/1/19/1373 20190624 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
